Is NRXS or CARL more profitable?

Carlsmed has a net margin of -57.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Carlsmed -57.76% -60.74% -29.84%

Is SGHT or NRXS more profitable?

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% NeurAxis -492.76% N/A -641.25%

Does the media prefer SGHT or NRXS?

In the previous week, Sight Sciences had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Sight Sciences and 1 mentions for NeurAxis. Sight Sciences' average media sentiment score of 0.63 beat NeurAxis' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NRXS or TMCI?

In the previous week, Treace Medical Concepts had 4 more articles in the media than NeurAxis. MarketBeat recorded 5 mentions for Treace Medical Concepts and 1 mentions for NeurAxis. Treace Medical Concepts' average media sentiment score of 1.34 beat NeurAxis' score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Treace Medical Concepts 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXS or CV more profitable?

CapsoVision has a net margin of -198.87% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% CapsoVision -198.87% N/A -136.03%

Does the media refer more to NRXS or CV?

In the previous week, CapsoVision had 5 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for CapsoVision and 1 mentions for NeurAxis. CapsoVision's average media sentiment score of 1.53 beat NeurAxis' score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CapsoVision 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CNXU or NRXS more profitable?

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets Conexeu Sciences N/A N/A N/A NeurAxis -492.76% N/A -641.25%

Does the media favor CNXU or NRXS?

In the previous week, Conexeu Sciences had 3 more articles in the media than NeurAxis. MarketBeat recorded 4 mentions for Conexeu Sciences and 1 mentions for NeurAxis. Conexeu Sciences' average media sentiment score of 0.34 beat NeurAxis' score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NeurAxis (NRXS) Competitors

$6.85 -0.30 (-4.20%)

As of 09:55 AM Eastern

Compare

NRXS vs. CARL, SGHT, TMCI, CV, and CNXU

Should you buy NeurAxis stock or one of its competitors? MarketBeat compares NeurAxis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeurAxis include Carlsmed (CARL), Sight Sciences (SGHT), Treace Medical Concepts (TMCI), CapsoVision (CV), and Conexeu Sciences (CNXU). These companies are all part of the "medical equipment" industry.

How does NeurAxis compare to Carlsmed?

NeurAxis (NASDAQ:NRXS) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, NeurAxis and NeurAxis both had 1 articles in the media. Carlsmed's average media sentiment score of 0.94 beat NeurAxis' score of 0.00 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
NeurAxis	Neutral
Carlsmed	Positive

11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeurAxis presently has a consensus price target of $13.00, suggesting a potential upside of 89.78%. Carlsmed has a consensus price target of $18.75, suggesting a potential upside of 62.99%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Carlsmed has a net margin of -57.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Carlsmed	-57.76%	-60.74%	-29.84%

NeurAxis has higher earnings, but lower revenue than Carlsmed. NeurAxis is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.81	-$14.63M	-$0.81	N/A
Carlsmed	$50.51M	6.19	-$29.63M	-$2.51	N/A

Summary

NeurAxis beats Carlsmed on 9 of the 14 factors compared between the two stocks.

How does NeurAxis compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sight Sciences currently has a consensus price target of $8.25, indicating a potential upside of 51.52%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 89.78%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Sight Sciences had 2 more articles in the media than NeurAxis. MarketBeat recorded 3 mentions for Sight Sciences and 1 mentions for NeurAxis. Sight Sciences' average media sentiment score of 0.63 beat NeurAxis' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has lower revenue, but higher earnings than Sight Sciences. NeurAxis is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$79.55M	3.72	-$38.43M	-$0.71	N/A
NeurAxis	$4.28M	19.81	-$14.63M	-$0.81	N/A

Summary

Sight Sciences beats NeurAxis on 10 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Treace Medical Concepts?

NeurAxis (NASDAQ:NRXS) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NeurAxis has higher earnings, but lower revenue than Treace Medical Concepts. NeurAxis is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.81	-$14.63M	-$0.81	N/A
Treace Medical Concepts	$207.32M	1.44	-$59M	-$0.97	N/A

In the previous week, Treace Medical Concepts had 4 more articles in the media than NeurAxis. MarketBeat recorded 5 mentions for Treace Medical Concepts and 1 mentions for NeurAxis. Treace Medical Concepts' average media sentiment score of 1.34 beat NeurAxis' score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Treace Medical Concepts	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeurAxis has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

NeurAxis presently has a consensus price target of $13.00, indicating a potential upside of 89.78%. Treace Medical Concepts has a consensus price target of $4.77, indicating a potential upside of 3.70%. Given NeurAxis' stronger consensus rating and higher probable upside, research analysts plainly believe NeurAxis is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Treace Medical Concepts has a net margin of -29.44% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

Summary

NeurAxis beats Treace Medical Concepts on 8 of the 15 factors compared between the two stocks.

How does NeurAxis compare to CapsoVision?

NeurAxis (NASDAQ:NRXS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

NeurAxis presently has a consensus price target of $13.00, suggesting a potential upside of 89.78%. CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 34.18%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CapsoVision had 5 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for CapsoVision and 1 mentions for NeurAxis. CapsoVision's average media sentiment score of 1.53 beat NeurAxis' score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

NeurAxis has higher earnings, but lower revenue than CapsoVision. NeurAxis is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.81	-$14.63M	-$0.81	N/A
CapsoVision	$13.55M	23.36	-$25.32M	-$2.34	N/A

CapsoVision has a net margin of -198.87% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
CapsoVision	-198.87%	N/A	-136.03%

Summary

CapsoVision beats NeurAxis on 8 of the 14 factors compared between the two stocks.

How does NeurAxis compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and NeurAxis (NASDAQ:NRXS) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Conexeu Sciences has higher earnings, but lower revenue than NeurAxis. Conexeu Sciences is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A
NeurAxis	$4.28M	19.81	-$14.63M	-$0.81	N/A

Conexeu Sciences presently has a consensus target price of $20.00, indicating a potential upside of 84.69%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 89.78%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
NeurAxis	-492.76%	N/A	-641.25%

11.8% of NeurAxis shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Conexeu Sciences had 3 more articles in the media than NeurAxis. MarketBeat recorded 4 mentions for Conexeu Sciences and 1 mentions for NeurAxis. Conexeu Sciences' average media sentiment score of 0.34 beat NeurAxis' score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeurAxis beats Conexeu Sciences on 6 of the 11 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Electromedical equipment Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.83M	$77.23M	$6.78B	$12.55B
Dividend Yield	N/A	N/A	2.68%	9.45%
P/E Ratio	-3.72	9.40	27.08	24.36
Price / Sales	19.81	192.39	509.19	91.03
Price / Cash	N/A	41.36	48.63	60.00
Price / Book	-25.37	5.07	10.82	6.31
Net Income	-$14.63M	-$5.50M	$3.59B	$331.55M
7 Day Performance	-4.99%	-3.67%	-1.77%	-0.71%
1 Month Performance	2.09%	2.46%	3.74%	0.16%
1 Year Performance	189.03%	105.12%	27.46%	19.66%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	1.4176 of 5 stars	$6.85 -4.2%	$13.00 +89.8%	+183.7%	$84.83M	$4.28M	N/A	19
CARL Carlsmed	2.3172 of 5 stars	$12.11 -3.7%	$18.75 +54.8%	N/A	$341.71M	$50.51M	N/A	100
SGHT Sight Sciences	3.6508 of 5 stars	$5.35 flat	$8.25 +54.2%	+57.2%	$291.09M	$77.36M	N/A	210
TMCI Treace Medical Concepts	2.6799 of 5 stars	$4.28 -2.9%	$4.77 +11.4%	-23.5%	$286.09M	$212.69M	N/A	250	News Coverage Positive News Short Interest Decrease
CV CapsoVision	2.9881 of 5 stars	$6.13 +8.1%	$8.50 +38.7%	+37.9%	$283.29M	$13.55M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. CARL, SGHT, TMCI, CV, and CNXU

How does NeurAxis compare to Carlsmed?

Summary

How does NeurAxis compare to Sight Sciences?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Summary

How does NeurAxis compare to CapsoVision?

Summary

How does NeurAxis compare to Conexeu Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. CARL, SGHT, TMCI, CV, and CNXU

How does NeurAxis compare to Carlsmed?

Does the media favor NRXS or CARL?

Do institutionals and insiders hold more shares of NRXS or CARL?

Do analysts rate NRXS or CARL?

Is NRXS or CARL more profitable?

Which has stronger earnings and valuation, NRXS or CARL?

Summary

How does NeurAxis compare to Sight Sciences?

Do insiders and institutionals believe in SGHT or NRXS?

Do analysts rate SGHT or NRXS?

Does the media prefer SGHT or NRXS?

Which has more volatility and risk, SGHT or NRXS?

Is SGHT or NRXS more profitable?

Which has preferable earnings & valuation, SGHT or NRXS?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Do institutionals and insiders believe in NRXS or TMCI?

Which has higher valuation & earnings, NRXS or TMCI?

Does the media favor NRXS or TMCI?

Which has more risk & volatility, NRXS or TMCI?

Do analysts prefer NRXS or TMCI?

Is NRXS or TMCI more profitable?

Summary

How does NeurAxis compare to CapsoVision?

Do analysts recommend NRXS or CV?

Do insiders & institutionals have more ownership in NRXS or CV?

Does the media refer more to NRXS or CV?

Which has better valuation & earnings, NRXS or CV?

Is NRXS or CV more profitable?

Summary

How does NeurAxis compare to Conexeu Sciences?

Which has better earnings & valuation, CNXU or NRXS?

Do analysts rate CNXU or NRXS?

Is CNXU or NRXS more profitable?

Do insiders and institutionals believe in CNXU or NRXS?

Does the media favor CNXU or NRXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools